Elucidating the direct effects of the novel HDAC inhibitor bocodepsin (OKI-179) on T cells to rationally design regimens for combining with immunotherapy

Histone deacetylase inhibitors (HDACi) are currently being explored for the treatment of both solid and hematological malignancies. Although originally thought to exert cytotoxic responses through tumor-intrinsic mechanisms by increasing expression of tumor suppressor genes, several studies have dem...

Whakaahuatanga katoa

Ngā taipitopito rārangi puna kōrero

Ngā kaituhi matua:	Nisha Holay, Alexander Somma, Mark Duchow, Milad Soleimani, Anna Capasso, Srividya Kottapalli, Joshua Rios, Uma Giri, Jennifer Diamond, Anna Schreiber, Anthony D. Piscopio, Carla Van Den Berg, S. Gail Eckhardt, Todd A. Triplett
Hōputu:	Artigo
Reo:	Inglês
I whakaputaina:	Frontiers Media S.A. 2023-09-01
Rangatū:	Frontiers in Immunology
Ngā marau:	T cell colorectal cancer HDAC HDAC inhibitors cancer immunotherapy
Urunga tuihono:	https://www.frontiersin.org/articles/10.3389/fimmu.2023.1260545/full
Ngā Tūtohu:	Tāpirihia he Tūtohu Kāore He Tūtohu, Me noho koe te mea tuatahi ki te tūtohu i tēnei pūkete!